Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 116Stomach Neoplasms 21HER2-positive Breast Cancer 14Neoplasms 12Neoplasm Metastasis 12Colorectal Neoplasms 11Esophageal Neoplasms 9Triple Negative Breast Neoplasms 5Lung Neoplasms 5Colonic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Rectal Neoplasms 4Ovarian Neoplasms 4Meningeal Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Inflammatory Breast Neoplasms 3Hematologic Neoplasms 3Gallbladder Neoplasms 3Breast Diseases 3Anatomic Stage I Breast Cancer AJCC v8 3

Interventions

trastuzumab deruxtecan 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Cisplatin 2Capecitabine 2pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Trastuzumab × 1 year × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡